SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Newton A. C.)
 

Sökning: WFRF:(Newton A. C.) > (2010-2014) > Angiotensin-Convert...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005038naa a2200529 4500
001oai:DiVA.org:uu-294665
003SwePub
008160526s2016 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:29021049-96bf-40e6-aa49-e55f4ef3dc0b
009oai:prod.swepub.kib.ki.se:133311833
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2946652 URI
0247 a https://doi.org/10.1016/j.jacc.2016.01.0502 DOI
0247 a https://lup.lub.lu.se/record/29021049-96bf-40e6-aa49-e55f4ef3dc0b2 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1333118332 URI
040 a (SwePub)uud (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Evans, Marieu Karolinska Institutet,Karolinska Institute4 aut
2451 0a Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction
264 1b Elsevier BV,c 2016
338 a print2 rdacarrier
520 a BACKGROUND There is no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) should be used for secondary prevention in all or in only high-risk patients after an acute myocardial infarction (AMI).OBJECTIVES This study sought to investigate whether ACEI/ARB treatment after AMI is associated with better outcomes across different risk profiles, including the entire spectrum of estimated glomerular filtration rates.METHODS This study evaluated discharge and continuous follow-up data on ACEI/ARB use among AMI survivors (2006 to 2009) included in a large Swedish registry. The association between ACEI/ARB treatment and outcomes (mortality, myocardial infarction, stroke, and acute kidney injury [AKI]) was studied using Cox proportional hazards models (intention-to-treat and as treated).RESULTS In total, 45,697 patients (71%) were treated with ACEI/ARB. The 3-year mortality was 19.8% (17.4% of ACEI/ARB users and 25.4% of nonusers). In adjusted analysis, significantly better survival was observed for patients treated with ACEI/ARB (3-year hazard ratio: 0.80; 95% confidence interval: 0.77 to 0.83). The survival benefit was consistent through all kidney function strata, including dialysis patients. Overall, those treated with ACEI/ARB also had lower 3-year risk for myocardial infarction (hazard ratio: 0.91; 95% confidence interval: 0.87 to 0.95), whereas treatment had no significant effect on stroke risk. The crude risk for AKI was in general low (2.5% and 2.0% for treated and nontreated, respectively) and similar across estimated glomerular filtration rate categories but was significantly higher with ACEI/ARB treatment. However, the composite outcome of AKI and mortality favored ACEI/ARB treatment.CONCLUSIONS Treatment with ACEI/ARB after AMI was associated with improved long-term survival, regardless of underlying renal function, and was accompanied by low rates of adverse renal events.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a chronic kidney disease
653 a mortality
653 a risk profile
653 a survival analysis
7001 a Carrero, Juan-Jesusu Karolinska Institutet,Karolinska Institute4 aut
7001 a Szummer, Karolinau Karolinska Institutet,Karolinska Institute4 aut
7001 a Åkerblom, Axelu Uppsala University,Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)axeak985
7001 a Edfors, Robertu Karolinska Institutet,Karolinska Institute4 aut
7001 a Spaak, Jonasu Karolinska Institutet,Karolinska Institute4 aut
7001 a Jacobson, Stefan H.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Andell, Pontusu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-poa
7001 a Lindhagen, Larsu Uppsala University,Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)lla11670
7001 a Jernberg, Tomasu Karolinska Institutet,Karolinska Institute4 aut
7102 a Karolinska Institutetb Karolinska Institute4 org
7730 t Journal of the American College of Cardiologyd : Elsevier BVg 67:14, s. 1687-1697q 67:14<1687-1697x 0735-1097x 1558-3597
8564 u https://doi.org/10.1016/j.jacc.2016.01.050
8564 u http://dx.doi.org/10.1016/j.jacc.2016.01.050y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-294665
8564 8u https://doi.org/10.1016/j.jacc.2016.01.050
8564 8u https://lup.lub.lu.se/record/29021049-96bf-40e6-aa49-e55f4ef3dc0b
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:133311833

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy